Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Zeev's Turnips - No Politics -- Ignore unavailable to you. Want to Upgrade?

To: sylvester80 who wrote (92265)	7/8/2002 12:24:51 AM
From: Softechie	Read Replies (3) \| Respond to of 99280

Merck Booked $12.4 Billion in Revenue It Never Collected Drug giant Merck & Co . recorded $12.4 billion in revenue from the company's pharmacy-benefits unit over the past three years that the subsidiary never actually collected, according to a filing with the Securities and Exchange Commission, Monday's Wall Street Journal reported. ADVERTISEMENT Merck's Medco unit, which manages pharmacy-benefit programs for employers and health insurers, included as part of its revenue the co -payments collected by pharmacies from patients, even though Medco doesn't receive those funds. Between 1999 and 2001, co -payments represented nearly 10% of Merck's overall reported revenue. Merck first disclosed the accounting treatment in an April SEC filing as it prepared to sell 20% of Medco in an initial public offering. But it wasn't until a subsequent SEC filing on Friday that the company said exactly how much revenue was involved. Merck, based in Whitehouse Station, N.J. , says its revenue-recognition policy conforms to generally accepted accounting principles. The company says the accounting treatment has no effect on its net income, because it subtracts the same amount as an expense. Medco is the country's second-largest pharmacy- benefits manager, with 65 million members. Medco reported revenue last year of $ 29.69 billion, or 59% of Merck's $50.69 billion in revenue. "For a company such as Merck to reflect as revenues in its financial statements billions of dollars of co -payments a customer makes directly to another company, the pharmacy, which the pharmacy collects and never remits to Merck, just does not reflect the economics of what is occurring," said Lynn Turner, a former chief accountant at the SEC who is now an accounting professor and director of the Center for Quality Financial Reporting at Colorado State University in Fort Collins. "If that is what the SEC accepts, then investors are in trouble and our financial reporting indeed needs improving," he said. Medco's accounting practice echoes a recent case involving Edison Schools Inc., a commercial operator of public schools, which was booking as revenue funds that school districts paid directly for teacher salaries and other costs. The SEC in May found that Edison "failed to disclose that a substantial portion of its reported revenues consist of payments that never reach Edison." Although Edison's accounting practice, which didn't affect net income, conformed to generally accepted accounting principles, the SEC said that "technical compliance with GAAP" doesn't insulate a company from enforcement action if it makes filings "that mischaracterize its business or omit significant information." The SEC ordered Edison to add a director of internal audit to its management team. The agency said that Edison would exclude most of those payments from its reported revenue in the future. There isn't any indication that regulators have an issue with Medco's or Merck's accounting. The SEC hasn't asserted that inclusion of co -payments in revenues are inappropriate or not in accordance with GAAP, according to a Merck official. SEC officials couldn't be reached to comment late Sunday. A pharmacy-benefits manager such as Medco uses the combined buying power of millions of people in its plans to extract discounts and rebates from drug makers and pharmacies. These companies then pass on some of the savings to clients -- employers and health-insurance companies -- looking to save money on prescription drug costs. Medco's revenue in question is the co -payment -- $10 to $15 is typical in the industry -- paid by consumers with a prescription drug card to their retail pharmacy to cover their portion of the cost of a drug under an insurance plan. The pharmacy keeps the entire amount of the co -payment. Merck contends that it has legal liabilities for the co -payment under certain circumstances, such as if it transmits electronically to the pharmacist incorrect information about how much co -payment the pharmacist should collect. But in its SEC filing, the company said it doesn't face a "credit risk," which would force it to reimburse pharmacies if a customer skipped out on making the co -payment. The disclosure from Merck comes amid heightened scrutiny over many companies' accounting policies after several high-profile scandals. Last week, the SEC ordered that chief executive officers and chief financial officers of more than 900 of the nation's largest companies must swear under oath in writing that the numbers in their companies' recent financial reports are correct. Merck declined to say whether the SEC required it to disclose the amounts of the co -payments in its latest filing, its fourth amended prospectus for the planned Medco initial public offering. But Kenneth C. Frazier, Merck's general counsel, said the latest filing has been thoroughly reviewed by the agency and " reflects the discussions we had with the SEC" over the co -payments. "We are proceeding with the offering and hope to price this week. However, we can't comment further because we are in the quiet period," he said. An SEC spokesman said the commission's approval of the latest filing is still pending. -- Barbara Martinez, staff reporter of The Wall Street Journal, contributed to this report.

To: sylvester80 who wrote (92265)	7/8/2002 12:42:16 AM
From: KyrosL	Respond to of 99280

What Reliant did can hardly be classified as fraud. Inflating revenues and costs by the same amount, has no effect on profits and cash flow, and is not the same as what Worldcom did. Worldcom inflated profits and cash flow by $3.4 billion. The energy trading companies reported inflated revenues and corresponding costs, not inflated profits and cash flow. A wash trade involves an equal amount of cash on both sides of the ledger. In fact, wash sales actually hurt energy companies in the eyes of those that can read financial statements. That's because increased revenues from wash sales resulted in no increased profits or cash flow, which is what counts for knowledgeable investors. Knowledgeable investors look at margins, and wash sales are not good for margins. Kyros